Universitätsfrauenklinik Regensburg
Welcome,         Profile    Billing    Logout  
 0 Trials 
4 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Seitz, Stephan
HER2CLIMB-05, NCT05132582 / 2021-002491-39: A Study of Tucatinib or Placebo With Trastuzumab and Pertuzumab for Metastatic HER2+ Breast Cancer

Calendar Jan 2025 - Dec 2025: From MOUNTAINEER-02 trial in combination with Herceptin and Cyramza for metastatic HER2+ gastric cancer
Active, not recruiting
3
654
Europe, Canada, Japan, US, RoW
Tucatinib, TUKYSA, ONT-380, ARRY-380, Trastuzumab, Herceptin, Herceptin Hylecta, Pertuzumab, Perjeta, Combination product: Trastuzumab + Pertuzumab, Phesgo, Placebo
Seagen Inc., Merck Sharp & Dohme LLC
HER2 Positive Breast Cancer
05/25
10/27
NCT04971161 / 2020-004960-24: Allogeneic ABCB5-positive Dermal Mesenchymal Stromal Cells for Treatment of CVU (Phase IIb)

Active, not recruiting
2
152
Europe
allo-APZ2-CVU, Skin-derived ABCB5-positive dermal mesenchymal stromal cells, Placebo
RHEACELL GmbH & Co. KG, FGK Clinical Research GmbH
Skin Ulcer Venous Stasis Chronic
06/26
06/26
ECLAT, NCT03438474: Endometrial Cancer Lymphadenectomy Trial

Recruiting
N/A
640
Europe, Japan, RoW
Standard surgical procedure for endometrial cancer, systematic lymphadenectomy (LNE)
Philipps University Marburg, German Cancer Aid
Cancer of Endometrium Stage I, Cancer of Endometrium Stage II
02/28
02/29
CATCH, NCT05652569: Implementation of Genomics-guided Precision Medicine in Metastatic Breast Cancer

Recruiting
N/A
5000
Europe
Genomic Profiling / Sequencing
German Cancer Research Center, University Hospital Heidelberg
Metastatic Breast Cancer
12/30
12/30

Download Options